Declining tuberculosis incidence among people receiving HIV care and treatment services in East Africa, 2007-2012

Journal of Acquired Immune Deficiency Syndromes

Volumn 71, Issue 4, 2016, Pages e96-e106

  Saito, Suzue ^a   Mpofu, Philani ^b   Jane Carter, E ^c,d   Diero, Lameck ^e   Wools Kaloustian, Kara K ^b   Yiannoutsos, Constantin T ^f   Beverly, Musick S ^b   Tsiouris, Simon ^g   Somi, Geoffrey R ^h   Ssali, John ⁱ   Nash, Denis ^j   Elul, Batya ^k  

^a Och Spine at New York Presbyterian Hospitals   (United States)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c BROWN UNIVERSITY   (United States)

^d MOI UNIVERSITY   (Kenya)

^e ACADEMIC MODEL PROVIDING ACCESS TO HEALTHCARE AMPATH   (Kenya)

^f INDIANA UNIVERSITY   (United States)

^g Ridgewood Infectious Diseases   (United States)

^h National AIDS Control Programme (NACP)   (Tanzania)

ⁱ Masaka Regional Referral Hospital   (Uganda)

^j CITY UNIVERSITY OF NEW YORK   (United States)

^k NONE   (United States)

more..

Author keywords

ART; HIV; Sub Saharan Africa; TB incidence rates; TB HIV; Tuberculosis

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; COTRIMOXAZOLE; ISONIAZID; TUBERCULOSTATIC AGENT;

ADULT; AFRICA; ARTICLE; FEMALE; HEALTH CARE ACCESS; HEALTH CARE FACILITY; HEALTH SERVICE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; INFECTION RISK; KENYA; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NAMED GROUPS OF PERSONS; PATIENT CARE; PEOPLE LIVING WITH HIV; PRIORITY JOURNAL; TANZANIA; TUBERCULOSIS; UGANDA; URBAN POPULATION; WORLD HEALTH ORGANIZATION; ADOLESCENT; COMPLICATION; HIV INFECTIONS; RETROSPECTIVE STUDY; TIME FACTOR; YOUNG ADULT;

ADOLESCENT; ADULT; ANTI-HIV AGENTS; FEMALE; HIV INFECTIONS; HUMANS; INCIDENCE; KENYA; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TANZANIA; TIME FACTORS; TUBERCULOSIS; UGANDA; YOUNG ADULT;

EID: 84960286066     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0000000000000896     Document Type: Article

References (46)

1. Getahun H, Gunneberg C, Granich R, et al. HIV infection-associated tuberculosis: the epidemiology and the response. Clin Infectious Dis. 2010;50(suppl 3):S201-S207.
2. Corbett EL, Marston B, Churchyard GJ, et al. Tuberculosis in sub-Saharan Africa: opportunities, challenges, and change in the era of antiretroviral treatment. Lancet. 2006;367:926-937.
3. WHO. Global Tuberculosis Control: Surveillance, Planning Financing. 2005. Available at: http://www.who.int/tb/publications/global-report/2005/download-centre/en/. Accessed May 22, 2014.
4. Jones JL, Hanson DL, Dworkin MS, et al. Adult/Adolescent Spectrum of HIVDG. HIV-associated tuberculosis in the era of highly active antiretroviral therapy. The Adult/Adolescent Spectrum of HIV Disease Group. Int J Tuberc Lung Dis. 2000;4:1026-1031.
5. Lawn SD, Badri M, Wood R. Tuberculosis among HIV-infected patients receiving HAART: long term incidence and risk factors in a South African cohort. AIDS. 2005;19:2109-2116.
6. Lawn SD, Myer L, Edwards D, et al. Short-term and long-term risk of tuberculosis associated with CD4 cell recovery during antiretroviral therapy in South Africa. AIDS. 2009;23:1717-1725.
7. Girardi E, Antonucci G, Vanacore P, et al. Impact of combination antiretroviral therapy on the risk of tuberculosis among persons with HIV infection. AIDS. 2000;14:1985-1991.
8. Santoro-Lopes G, de Pinho AM, Harrison LH, et al. Reduced risk of tuberculosis among Brazilian patients with advanced human immunodeficiency virus infection treated with highly active antire-troviral therapy. Clin Infect Dis. 2002;34:543-546.
9. Golub JE, Saraceni V, Cavalcante SC, et al. The impact of antiretroviral therapy and isoniazid preventive therapy on tuberculosis incidence in HIV-infected patients in Rio de Janeiro, Brazil. AIDS. 2007;21:1441-1448.
10. Miranda A, Morgan M, Jamal L, et al. Impact of antiretroviral therapy on the incidence of tuberculosis: the Brazilian experience, 1995-2001. PLoS One. 2007;2:e826.
11. Muga R, Ferreros I, Langohr K, et al. Changes in the incidence of tuberculosis in a cohort of HIV-seroconverters before and after the introduction of HAART. AIDS. 2007;21:2521-2527.
12. Moreno S, Jarrin I, Iribarren JA, et al. Incidence and risk factors for tuberculosis in HIV-positive subjects by HAART status. Int J Tuberc Lung Dis. 2008;12:1393-1400.
13. Golub JE, Pronyk P, Mohapi L, et al. Isoniazid preventive therapy, HAART and tuberculosis risk in HIV-infected adults in South Africa: a prospective cohort. AIDS. 2009;23:631-636.
14. Lawn SD, Wood R, De Cock KM, et al. Antiretrovirals and isoniazid preventive therapy in the prevention of HIV-associated tuberculosis in settings with limited health-care resources. Lancet Infect Dis. 2010;10: 489-498.
15. Lawn SD, Harries AD, Williams BG, et al. Antiretroviral therapy and the control of HIV-associated tuberculosis. Will ART do it? Int J Tuberc Lung Dis. 2011;15:571-581.
16. UNAIDS. The Gap Report 2014. 2014. Available at: http://www.unaids.org/sites/default/files/en/media/unaids/contentassets/documents/unaidspublication/2014/UNAIDS-Gap-report-en.pdf. Accessed September 26, 2015.
17. WHO. Global Tuberculosis Report. 2014:15-16. Available at: http://apps. who.int/iris/bitstream/10665/91355/1/9789241564656-eng.pdf. Accessed May 29, 2014.
18. Murray CJ, Ortblad KF, Guinovart C, et al. Global, regional, and national incidence and mortality for HIV, tuberculosis, and malaria during 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2014;384:1005-1070.
19. Middelkoop K, Wood R, Bekker LG. The impact of antiretroviral treatment programs on tuberculosis notification rates. Int J Tuberc Lung Dis. 2011;15:1714; author reply 1714-1715.
20. Zachariah R, Bemelmans M, Akesson A, et al. Reduced tuberculosis case notification associated with scaling up antiretroviral treatment in rural Malawi. Int J Tuberc Lung Dis. 2011;15:933-937.
21. Yuen CM, Weyenga HO, Kim AA, et al. Comparison of trends in tuberculosis incidence among adults living with HIV and adults without HIV-Kenya, 1998-2012. PLoS One. 2014;9:e99880.
22. Badri M, Wilson D, Wood R. Effect of highly active antiretroviral therapy on incidence of tuberculosis in South Africa: a cohort study. Lancet. 2002;359:2059-2064.
23. Antonucci G, Girardi E, Raviglione MC, et al. Risk factors for tuberculosis in HIV-infected persons. A prospective cohort study. JAMA. 1995;274:143-148.
24. Grant AD, Charalambous S, Fielding KL, et al. Effect of routine isoniazid preventive therapy on tuberculosis incidence among HIV-infected men in South Africa: a novel randomized incremental recruitment study. JAMA. 2005;293:2719-2725.
25. Grimwade K, Sturm AW, Nunn AJ, et al. Effectiveness of cotrimoxazole prophylaxis on mortality in adults with tuberculosis in rural South Africa. AIDS. 2005;19:163-168.
26. Gupta A, Wood R, Kaplan R, et al. Tuberculosis incidence rates during 8 years of follow-up of an antiretroviral treatment cohort in South Africa: comparison with rates in the community. PLoS One. 2012;7:e34156.
27. Egger M, Ekouevi DK, Williams C, et al. Cohort Profile: the international epidemiological databases to evaluate AIDS (IeDEA) in sub-Saharan Africa. Int J Epidemiol. 2012;41:1256-1264.
28. Africa I-E. Site Assessment Questionnaires. 2014. Available at: https://www. iedea-ea.org/joomla/index.php?option=com-content&view=category&id=74: site-assessment-questionnaires&Itemid=62&layout=default. Accessed 8/31/2014, 2014.
29. WHO. Global Health Observatory Data Repository: Cases: Incidence Data by Country (All Years). 2013. Available at: http://apps.who.int/gho/data/view.main.57040ALL?lang=en. Accessed 6/10/2014, 2014.
30. Boyer P, Parkin DM. Statistical methods for registries In: Jensen DMP OM, MacLennan R, Muir CS, Skeet RG, eds. Cancer Registration: Principles and Methods. Lyon, France: International Agency for Research on Cancer; 1991:141.
31. WHO. Guidelines on Co-Trimoxazole Prophylaxis for HIV-Related Infections Among Children, Adolescents and Adults: Recommendations for a Public Health Approach. 2006:p19-20. Available at: http://www. who.int/hiv/pub/plhiv/ctx/en/. Accessed May 28, 2014.
32. Yiannoutsos CT, An MW, Frangakis CE, et al. Sampling-based approaches to improve estimation of mortality among patient dropouts: experience from a large PEPFAR-funded program in Western Kenya. PLoS One. 2008;3:e3843.
33. World Bank. Antiretroviral Therapy Coverage (% of People Living with HIV). 2015; Available at: http://data.worldbank.org/indicator/SH.HIV. ARTC.ZS. Accessed September 29, 2015.
34. Lawn SD, Kranzer K, Wood R. Antiretroviral therapy for control of the HIV-associated tuberculosis epidemic in resource-limited settings. Clin Chest Med. 2009;30:685-699, viii.
35. Suarez PG, Watt CJ, Alarcon E, et al. The dynamics of tuberculosis in response to 10 years of intensive control effort in Peru. J Infect Dis. 2001;184:473-478.
36. Lonnroth K, Jaramillo E, Williams BG, et al. Drivers of tuberculosis epidemics: the role of risk factors and social determinants. Soc Sci Med. 2009;68:2240-2246.
37. Lonnroth K, Williams BG, Cegielski P, et al. A consistent log-linear relationship between tuberculosis incidence and body mass index. Int J Epidemiol. 2010;39:149-155.
38. Van Rie A, Westreich D, Sanne I. Tuberculosis in patients receiving antiretroviral treatment: incidence, risk factors, and prevention strategies. J Acquir Immune Defic Syndr. 2011;56:349-355.
39. Lienhardt C, Bennett S, Del Prete G, et al. Investigation of environmental and host-related risk factors for tuberculosis in Africa. 1. Methodological aspects of a combined design. Am J Epidemiol. 2002;155:1066-1073.
40. Gandhi NR, Moll AP, Lalloo U, et al. Successful integration of tuberculosis and HIV treatment in rural South Africa: the Sizonq'oba study. J Acquir Immune Defic Syndr. 2009;50:37-43.
41. Coetzee D, Hilderbrand K, Goemaere E, et al. Integrating tuberculosis and HIV care in the primary care setting in South Africa. Trop Med Int Health. 2004;9:A11-A15.
42. Allison PD. Multiple Imputation for Missing Data: A Cautionary Tale. Philadelphia, Pennsylvania: Sociology Department, University of Pennsylvania; 1999. Available at: http://www.ssc.upenn.edu/~allison/MultInt99.pdf. Accessed June 5, 2014.
43. Larson BA, Brennan A, McNamara L, et al. Early loss to follow up after enrollment in pre-ART care at a large public clinic in Johannesburg, South Africa. Trop Med Int Health. 2010;15(suppl 1):43-47.
44. Rosen S, Fox MP, Gill CJ. Patient retention in antiretroviral therapy programs in sub-Saharan Africa: a systematic review. PLoS Med. 2007; 4:e298.
45. Fox MP, Rosen S. Patient retention in antiretroviral therapy programs up to three years on treatment in sub-Saharan Africa, 2007-2009: systematic review. Trop Med Int Health. 2010;15 (suppl 1):1-15.
46. UNAIDS. Global Report: UNAIDS Report on the Global AIDS Epidemic 2013. 2013. Available at: http://www.unaids.org/sites/default/files/media-asset/UNAIDS-Global-Report-2013-en-1.pdf. Accessed October 2, 2015.